Portal de investigación
Glasdegib (GLAS) plus low-dose cytarabine (LDAC) in AML or MDS: BRIGHT AML 1003 final report and four-year overall survival (OS) follow-up.
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Heuser, M
- Robak, T
- Leber, B
- Fiedler, WM
- Pollyea, DA
- Brown, A
- O'Connell, A
- Ma, W
- Chan, G
- Cortes, JE
Grupos
Abstract
Abstract no disponible
Filiaciones
Filiaciones no disponibles
Campos de Estudio
Cita
Heuser,M,Robak,T,Montesinos,P,Leber,B,Fiedler,WM,Pollyea,DA,Brown,A et al. Glasdegib (GLAS) plus low-dose cytarabine (LDAC) in AML or MDS: BRIGHT AML 1003 final report and four-year overall survival (OS) follow-up. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). 2020. ELECTR NETWORK-MAY 29-31. TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103:LIPPINCOTT WILLIAMS & WILKINS. 2020.